Suresh Sharma, MD
Cardiovascular Disease · Lexington, KYNPI 1922394899
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Edwards Lifesciences at 39.0% of the total. Reporting peaked in 2022 at $4,752 and has fallen 61.3% since, to $1,839 in 2025.
Across 300 payments — averaging $49.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Boston Scientific$4K
- Medtronic$783
- Novartis$609
- Amgen$510
- Abbott$377
- plus $2K from 29 others
Across 16 payments — averaging $11,847 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cardiovascular Systems Inc.$190K
What the payments were for
- Consulting fees$5304%
- Travel & lodging$6,11341%
- Food & beverage$8,28555%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 38 | $5,816 |
| Boston Scientific | 81 | $4,490 |
| Medtronic | 13 | $783 |
| Novartis | 30 | $609 |
| Amgen | 24 | $510 |
| Abbott | 4 | $377 |
| Pfizer | 19 | $339 |
| E.r. Squibb & Sons, L.L.C. | 16 | $306 |
| Johnson & Johnson | 12 | $220 |
| Asahi Intecc USA, Inc. | 6 | $158 |
| Philips North America LLC | 4 | $135 |
| Abiomed | 2 | $126 |
| Heartflow, Inc. | 5 | $124 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $104 |
| Merck | 6 | $88 |
| Cardiovascular Systems Inc. | 2 | $87 |
| AstraZeneca | 5 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $76 |
| Kestra Medical Technology Services, Inc. | 3 | $60 |
| Actelion Pharmaceuticals US, Inc. | 2 | $47 |
| Boehringer Ingelheim | 3 | $45 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Lexicon Pharmaceuticals, Inc. | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Surmodics, Inc. | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Bridgebio Pharma, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Cvrx, Inc. | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Cleerly, Inc. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$4,706
- GENERAL - THERAPIES$1,474
- Watchman$1,264
- SYMPLICITY G3$280
- RESOLUTE ONYX$248
- WATCHMAN Access System$247
- INSPIRIS RESILIA aortic valve$151
- NAVITOR$141
- CROSSBOSS$140
- Impella$122
- PORTICO$117
- ONYX FRONTIER$115
How this compares
$14,928 in reported general payments places this provider in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 66 | $77,411 |
| XareltoRivaroxaban | 54 | $68,009 |
| Repatha SureclickEvolocumab | 20 | $26,662 |
| EntrestoSacubitril/Valsartan | 14 | $13,498 |
| BrilintaTicagrelor | 11 | $7,001 |
| Metoprolol Succinate | 198 | $2,414 |
| Atorvastatin Calcium | 188 | $1,615 |
| Ranolazine ErRanolazine | 20 | $1,529 |
| Rosuvastatin Calcium | 126 | $1,159 |
| ClopidogrelClopidogrel Bisulfate | 100 | $1,159 |
| Carvedilol | 108 | $893 |
| Ezetimibe | 36 | $670 |
| Losartan Potassium | 92 | $650 |
| Flecainide Acetate | 15 | $578 |
| Amlodipine Besylate | 93 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $339 | $77,41166 claims |
| Johnson & JohnsonXarelto | $220 | $68,00954 claims |
| NovartisEntresto | $609 | $13,49814 claims |
| AstraZenecaBrilinta | $76 | $7,00111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 258 cardiovascular disease providers in Kentucky.
Other cardiovascular disease in Lexington
- William SkinnerLexington$312K
- David MoliternoLexington$115K
- Andrew LeventhalLexington$43K
- John GurleyLexington$21K
- James CragerLexington$12K
- Kevin ScullyLexington$9K
- Nathan KustererLexington$8K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
- Prabodh MehtaElizabethtown$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.